Firalis

Firalis is a biotechnology company in Huningue, France, in the BioValley area on the France-Germany-Switzerland border near Basel. It discovers, develops and seeks regulatory qualification for biomarkers, and provides biomarker and CRO services alongside its own diagnostic products.

Its product range includes the MemoryLinc blood test for Alzheimer's Disease, the NeuroLincs lncRNA test for neurodegenerative diseases, the FIMICS lncRNA panel for cardiac disorders and toxicities, and the BIOPRED gene sequencing panel for inflammatory-autoimmune disorders. It also sells CE-marked and research-use-only ELISA kits, recombinant proteins, monoclonal antibodies and clinical study samples. Customers are pharmaceutical companies and healthcare professionals; the company states its products are not intended for self-testing by individuals. Firalis operates through a group that includes separate companies for multi-omics CRO services, mass spectrometry services, and cardiovascular and neurodegenerative biomarker R&D.

Firalis was founded in 2008 and has built its clinical network through R&D consortia it coordinated, including the SAFE-T biomarker qualification project co-funded by seven large pharmaceutical companies and the European Commission via IMI-JU. Its production facilities are described as ISO 9001, ISO 13485 and GMP compliant. Open roles are described in biology, in-vitro diagnostics, cardiovascular research, protein biochemistry, production, and administration and finance.

Product: Biomarker diagnostic tests, ELISA kits, recombinant proteins, antibodies and biomarker R&D services for pharmaceutical and clinical research.